MedTrace Logo

Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)

NCT04365257 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2023-04-10

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the efficacy and safety of prazosin to prevent cytokine storm syndrome and severe complications in hospitalized patients with Coronavirus disease 2019 (COVID-19).

Conditions

Interventions

DRUG

Prazosin

Participants in this arm will receive the study drug as outlined in the arm description.

OTHER

Standard of care

Participants in this arm will receive standard of care.

Sponsors & Collaborators

Principal Investigators

  • Chetan Bettegowda, MD/PhD · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-13
Primary Completion
2022-03-31
Completion
2022-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04365257 on ClinicalTrials.gov